Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. T ...

interest. Readers are encouraged to conduct their own independent research and consult qualified financial, legal, medical, or other professional advisers before making any investment or health-related decisions.Forward-looking statements referenced in this article are subject to risks and uncertainties, and actual results may differ materially. Past performance is not indicative of future results.For full disclosures, risk factors, and forward-looking statements, please visit: [https://moonage.media/discla ...

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation, with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, provides private aviation services, operating a fleet of executive jets and catering to both leisure and business clients [2]. Strategic Rationale - The acquisition is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter the growing private aviation market, projected to reach $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a third-party transfer of a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Details - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Memorandum of Understanding (MOU) to acquire a 51% stake in Arrow Aviation, a high-growth private aviation company, for approximately $5.8 million, marking a strategic entry into the private aviation sector [1][3]. Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing intranasal protective solutions, including innovative medical device hydrogels delivered as nasal sprays [5]. - Arrow Aviation is a leading provider of private aviation services with annual unaudited revenues of approximately $19 million and adjusted EBITDA of around $3 million, operating a fleet of executive jets and offering tailored VIP flights [2]. Strategic Expansion - The acquisition of Arrow Aviation is seen as a diversification opportunity for Polyrizon, allowing the company to leverage its financial position to enter a private aviation market projected to grow to $41.38 billion by 2030 [3]. - The proposed transaction includes arrangements for a Hawker 800 aircraft valued at $3.5 million and the forgiveness of outstanding shareholder debts by existing Arrow Aviation shareholders in exchange for convertible notes from Polyrizon [3]. Transaction Timeline - A definitive agreement is expected to be signed within 30 days of the MOU, subject to due diligence, with the closing of the acquisition anticipated to follow customary closing conditions [4].

Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]

Core Insights - Polyrizon Ltd. is committed to advancing its core intranasal medical pipeline while exploring strategic investment opportunities in sectors such as aviation, AI, and defense [1][2][3] - The company is focusing on high-potential sectors for initial investment efforts, while continuing to develop its medical devices, including products like PL-14 and PL-16 [2][3] - Polyrizon's Board of Directors has approved selective investments aimed at generating near-term revenues and enhancing financial stability, leveraging the company's strong cash position and debt-free balance sheet [3] Company Overview - Polyrizon is a development-stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask" in the nasal cavity, with ongoing development to improve bioadhesion and drug delivery [4]

Core Insights - Polyrizon Ltd. has completed the branding process for its PL-14 allergy blocker, which will be marketed as NASARIX™ [1][4] - NASARIX™ utilizes Polyrizon's proprietary Capture and Contain™ hydrogel technology, designed to create a protective barrier against allergens and viruses [2][5] - The establishment of the NASARIX™ brand is a significant milestone for Polyrizon, aiding in future commercialization and effective communication of the product's benefits [2][4] Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing innovative medical device hydrogels delivered as nasal sprays [5] - The company's C&C hydrogel technology aims to provide a barrier against viruses and allergens, functioning as a "biological mask" in the nasal cavity [5] - Polyrizon is also developing additional technology for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target™ [5]

Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].

Industry Overview - The 2025-2026 flu season in the United States is intensifying, primarily driven by a mutated strain of influenza A, leading to concerns about a challenging winter ahead [1] - As of late December 2025, the CDC estimates indicate that flu has caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide [1][2] - Flu activity is rising sharply, with outpatient visits for influenza-like illness significantly above baseline levels in many states [2] Vaccination and Public Health - Vaccination rates are lagging, with over 47 million doses administered, down approximately 3 million from the previous year, increasing vulnerability among the population [2] - The World Health Organization reports a global increase in influenza activity since October 2025, with influenza A viruses being the most prevalent [3] Company Spotlight: Polyrizon Ltd. - Polyrizon Ltd. is an Israeli biotech company developing innovative medical device hydrogels, specifically the PL-16 Viral Blocker, a non-pharmaceutical hydrogel nasal spray [4][8] - The PL-16 product creates a temporary physical barrier on the nasal mucosa, potentially capturing and containing respiratory viruses before they can infect cells, showing over 90% protection in preclinical studies [5][6] - On December 19, 2025, Polyrizon submitted a Pre-Request for Designation to the FDA for PL-16, aiming for potential over-the-counter status to reduce exposure to respiratory viruses [6] Market Potential and Innovation - The PL-16 product is designed to complement existing vaccines, masks, and hygiene practices, providing an additional layer of defense during high-activity seasons [6][7] - Experts emphasize the importance of layered protection, suggesting that innovations like Polyrizon's PL-16 could serve as a drug-free tool for both vaccinated and unvaccinated individuals [7]